|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our results provide evidence that the functionally relevant SNP in the NP-Y promoter gene affects body fat distribution and serum leptin levels in women, pointing towards possible behavioral effects of NPY in obesity.
|
23652383 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The objective of the present study was to evaluate the association of single nucleotide polymorphisms (SNPs) in the NPY gene with obesity, metabolic syndrome features, and inflammatory and cardiovascular disease (CVD) risk biomarkers in Spanish children.
|
23624317 |
2013 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that NPY mRNA expression was higher in obese than in normal weight humans (p<0.05) in both subcutaneous and visceral adipose tissues and was significantly greater in visceral when compared with subcutaneous fat in overall (p<0.01), obese (p<0.05) and normal weight humans (p<0.05).
|
23838112 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, upregulation of NPY may have an impact in anti-cancer treatment of neuroblastomas with VPA, and antagonizing hypothalamic NPY effects may help to ameliorate VPA-induced weight gain and obesity without interfering with the desired central effects of VPA.
|
23994577 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) is a neurotransmitter and enhances the development of obesity and other aspects of MetS.
|
22308535 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
These studies underscore the potential of (pGlu-Gln)-CCK-8 for the treatment of obesity-diabetes and suggest modulation of NPY and melanocortin related pathways may be involved in the observed beneficial effects.
|
23315994 |
2013 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Because NPY is a potent orexigenic peptide stimulating food intake, and genetic variation of the gene has been shown to influence development of obesity, we investigated the impact of NPY polymorphisms on antipsychotic-induced BWG.We analyzed 5 polymorphisms in the NPY gene (rs10551063, rs16147, rs5573, rs5574, and rs16475) in schizophrenia subjects (n = 226), treated mostly with clozapine and olanzapine for up to 14 weeks.
|
23277265 |
2013 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the role of two functional NPY polymorphisms, NPY-Leu7Pro (rs16139) and NPY-399C/T (rs16147) and obesity for the development of asthma as well as atherosclerosis in asthmatic and non-asthmatic subjects.
|
23122776 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Here, we sought to determine whether the effects of NPY on feeding and/or obesity are dissociable from effects on hepatic VLDL-TG secretion.
|
23074243 |
2012 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Conflicting evidence has been found for the association between polymorphisms of the NPY gene and obesity in humans.
|
21937627 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The neuropeptide Y system has proven to be one of the most important regulators of feeding behaviour and energy homeostasis, thus presenting great potential as a therapeutic target for the treatment of disorders such as obesity and at the other extreme, anorexia.
|
21545413 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, long-term interference with the NPY system to target obesity or cancer related aspects needs to consider potential side effects on bone health.
|
21439311 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, moderate down-regulation of NPY did not affect basal feeding or normal body weight gain but the response to food deprivation was compromised since fasting-induced hyperphagia was inhibited and fasting-induced decrease in locomotor activity was absent.These results highlight the importance of the physiological ARC NPY levels oscillations on feeding regulation, fasting response and body weight preservation, and are important for the design of therapeutic interventions for obesity that include the NPY.
|
21799827 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both overexpression of agouti-related peptide or neuropeptide Y in the paraventricular nucleus or lateral hypothalamus induce obesity in a neuropeptide- and nucleus specific manner.
|
21211526 |
2011 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression analysis did not reveal significant association with obesity and NPY single-nucleotide polymorphisms (SNPs) in the present study.
|
20531438 |
2010 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent research demonstrates that stress, acting through the neuropeptide Y (NPY) and glucocorticoid systems, potentiates the development of obesity and other aspects of metabolic syndrome in mice fed a high caloric, fat and sugar diet.
|
20881319 |
2010 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate that DMH NPY plays an important role in modulating food intake and energy balance and its dysregulation causes disordered energy balance leading to obesity.
|
19129396 |
2009 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Neuropeptide Y polymorphism significantly magnifies diabetes and cardiovascular disease risk in obesity: the Hoorn Study.
|
18043699 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Centrally administered NPY causes robust increases in food intake and body weight and, with chronic administration, can eventually produce obesity.
|
17785427 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
RGD |
Difference of NPY and its receptor gene expressions between obesity and obesity-resistant rats in response to high-fat diet.
|
17447163 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our findings show that life-long tonic repression of NPY system with a stable increase in leptin availability in the hypothalamus prevented the age-related and high fat-diet-induced obesity, hyperinsulinemia and diabetes and extended lifespan.
|
17979776 |
2007 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Ghrelin and NPY mRNA levels followed the same trend and were significantly higher in the hypothalamus in obese compared to lean subjects, suggesting a central origin for the increased protein content in the obese subjects.
|
16957407 |
2006 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The consistent findings among men suggest that the NPY Leu7Pro polymorphism (or another linked marker) might be involved in the development of obesity at younger ages.
|
16568137 |
2006 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in the ghrelin (GHRL) and neuropeptide Y (NPY) genes were examined in the same population-based case-control study of NHL to further explore the role of genes involved in energy homeostasis and obesity in susceptibility to NHL.
|
15894681 |
2005 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The regulation of NPY/NPY-R expression and function appears to be part of a complex system controlling multiple physiological functions, and its disruption might be relevant in the pathophysiology of disease states such as obesity.
|
12570784 |
2003 |